Royalty Pharma (NasdaqGS:RPRX) FY Conference January 13, 2026 12:45 PM ET Company ParticipantsChris Schott - Managing DirectorPablo Legorreta - Founder & CEONone - Company RepresentativeConference Call ParticipantsNone - AnalystChris SchottGood morning, everybody. I'm Chris Schott at JPMorgan, and it's my pleasure to be introducing Royalty Pharma today. It's a really unique business in our view, a company that's helping finance a lot of the innovation that's occurring across the biopharma space. From the co ...

Tenaya Therapeutics, Inc. (NASDAQ:TNYA) is one of the stocks under $1 that will explode. Morgan Stanley Reduces PT on Tenaya Therapeutics (TNYA), Keeps Constructive Stance on U.S. Small- to Mid-Cap Biotech Chaikom/Shutterstock.com On January 8, 2026, TheFly reported that Morgan Stanley reduced its price target on Tenaya Therapeutics, Inc. (NASDAQ:TNYA) from $5 to $2, while reiterating an ‘Overweight’ rating. The firm keeps its constructive stance on U.S. small- to mid-cap biotech in 2026, as it expects ...

U.S. Stock Market Performance - U.S. stocks traded higher, with the Dow Jones index gaining more than 250 points, closing up 1.66% at 49,183.51 [1] - The NASDAQ increased by 0.80% to 23,420.85, and the S&P 500 rose by 0.81% to 6,913.76 [1] Sector Performance - Energy shares experienced a gain of 2.9% on Monday [1] - Utilities stocks saw a decline of 2.2% [1] Commodity Market - Oil prices rose by 1.7% to $58.30 [4] - Gold increased by 2.9% to $4,454.40 [4] - Silver surged by 7.3% to $76.230, while copper rose by 5.1% to $5.9815 [4] European Market Performance - European shares were higher, with the eurozone's STOXX 600 gaining 0.94% [5] - Spain's IBEX 35 Index rose by 0.70%, London's FTSE 100 increased by 0.54%, Germany's DAX gained 1.34%, and France's CAC 40 climbed 0.20% [5] Asian Market Performance - Asian markets closed mostly higher, with Japan's Nikkei 225 gaining 2.97% [6] - Hong Kong's Hang Seng Index increased by 0.03%, China's Shanghai Composite surged by 1.38%, while India's BSE Sensex fell by 0.38% [6] Company-Specific Developments - Momentus Inc (NASDAQ:MNTS) shares surged 57% to $8.98 following the announcement of an additive-manufactured fuel tank for flight testing [8] - GH Research PLC (NASDAQ:GHRS) shares rose 17% to $15.43 after the FDA lifted the clinical hold on its Investigational New Drug Application [8] - VerifyMe Inc (NASDAQ:VRME) shares increased by 66% to $1.12 due to a strategic merger letter of intent with Open World [8] - Zenas Biopharma Inc (NASDAQ:ZBIO) shares dropped 57% to $14.94 after announcing Phase 3 INDIGO trial results [8] - Palisade Bio Inc (NASDAQ:PALI) shares fell 16% to $2.10, and Palvella Therapeutics Inc (NASDAQ:PVLA) decreased by 14% to $86.16 [8]

Core Viewpoint - The FDA has accepted a supplemental biologic license application for Tzield to expand its age indication to children as young as one year old, aiming to delay the onset of stage 3 type 1 diabetes in patients diagnosed with stage 2 T1D [1][2]. Group 1: FDA Review and Study Data - The priority review of Tzield highlights the urgent need for innovative therapies to prevent the progression of T1D, particularly in young patients [2]. - The application is supported by positive interim one-year data from the ongoing PETITE-T1D phase 4 study, which evaluates Tzield's safety and pharmacokinetics in young children [1][4]. - The target action date for the FDA's decision on the application is April 29, 2026 [1]. Group 2: Study Details - The PETITE-T1D study is a phase 4, single-arm, non-randomized, open-label trial designed to assess Tzield in children under eight years diagnosed with stage 2 T1D, characterized by the presence of T1D-related autoantibodies and dysglycaemia [4][12]. - The study has enrolled 23 participants, with a treatment regimen consisting of an intravenous infusion of Tzield once daily for 14 consecutive days, and individual follow-up may last up to 26 months [5]. Group 3: Tzield Overview - Tzield (teplizumab-mzwv) is a CD3-directed monoclonal antibody and the first disease-modifying therapy for autoimmune T1D, initially approved in the US in November 2022 for patients aged eight and older [6]. - The therapy is also approved in several countries, including China, the UK, Canada, and others, for delaying the onset of stage 3 T1D in the same population [6]. - If approved for younger patients, Tzield would be the first therapy to delay the onset of stage 3 T1D in children aged one and older diagnosed with stage 2 T1D [8].

Digital Assets and Crypto - The Trump administration aimed to establish the U.S. as the "crypto capital of the planet" through a Digital Financial Technology executive order, creating a national digital asset stockpile and a federal framework for stablecoins [2] - Bitcoin reached record highs above $100,000, leading to significant inflows into crypto-linked stocks like Coinbase Global, Inc. and Strategy, Inc. as the regulatory environment improved [3] Drones - The signing of two executive orders on June 6, 2025, promoted the drone sector by enforcing a "buy American" policy for federal drone procurement and banning foreign-manufactured drones in critical infrastructure, particularly targeting Chinese competitors [4] - The FAA was directed to fast-track beyond visual line of sight (BVLOS) regulations, unlocking economic potential for long-range delivery and industrial inspection [5] - Investors showed strong interest in drone stocks, with companies like AeroVironment, Inc. and Red Cat Holdings, Inc. experiencing sustained rallies, while tech-integrated firms like Axon Enterprise, Inc. reached all-time highs [6] - The administration announced plans to procure 300,000 low-cost attritable drones for the Pentagon, positioning the drone sector as a high-growth defense and logistics powerhouse [7] Health Care - The healthcare sector faced volatility due to executive orders aimed at lowering drug costs and reshuffling supply chains, including regulatory relief for domestic medicine production [8] - The "most-favored nation" pricing executive order linked U.S. prescription prices to the lowest costs in other developed nations, impacting stocks like Eli Lilly And Co. and Novo Nordisk A/S following deals to offer GLP-1 medications [9] - Health insurance companies like UnitedHealth Group Inc. experienced significant pressure, with stock prices dropping nearly 10% in December after a mandate to ease premiums was signaled [10]

Company Overview - Puma Biotechnology (PBYI) is valued at $303 million and focuses on cancer treatment, with its only marketed product being Nerlynx (neratinib), approved for early-stage HER2-positive breast cancer in the U.S. and the European Union [1][2] Product Development - Additional studies on Nerlynx are ongoing, targeting various breast cancer patient populations and other cancer types, while Puma has sub-licenses to commercialize Nerlynx in international markets [2] Stock Performance - PBYI stock has surged 91% over the past year, driven by technical momentum and speculative trading spikes, despite having weak fundamentals and stagnant revenue [6] Technical Indicators - The stock has received a "Buy" signal from Trend Seeker, and since this signal on December 9, the stock has gained 8.24% [3] Analyst Sentiment - Analyst sentiment is mixed, with most ratings being "Hold" or "Sell," indicating a lack of compelling long-term investment appeal due to declining earnings and reliance on a single product [6]

Market Overview - U.S. stocks traded lower, with the Dow Jones index falling more than 100 points, down 0.25% to 48,591.37, NASDAQ down 0.55% to 23,464.42, and S&P 500 down 0.34% to 6,906.41 [1] - Energy shares rose by 0.6%, while materials stocks fell by 1.1% [1] Real Estate Sector - U.S. pending home sales increased by 3.3% month-over-month in November, following a revised 2.4% gain in October, exceeding market estimates of a 1% gain [2][10] Commodity Market - Oil prices increased by 2.5% to $58.13, while gold prices decreased by 4.2% to $4,360.50. Silver fell by 6.8% to $71.945, and copper dropped by 4.6% to $5.5725 [5] European Market - European shares showed mixed results, with the eurozone's STOXX 600 gaining 0.1%, while Germany's DAX 40 fell by 0.1% [6] Asian Market - Asian markets closed mostly lower, with Japan's Nikkei 225 down 0.44% and Hong Kong's Hang Seng Index down 0.71% [7] Company Performance - CCSC Technology International Holdings Limited shares surged 93% to $0.2516 [9] - Brand Engagement Network, Inc. shares rose 77% to $2.1200 after a Vendor Services Project Agreement [9] - Society Pass Incorporated shares increased by 58% to $2.88 following the launch of TMG Social [9] - Mereo BioPharma Group plc shares dropped 89% to $0.2436 after failing to meet primary endpoints in clinical studies [9] - Ultragenyx Pharmaceutical Inc. shares fell 41% to $20.10 due to similar study results as Mereo [9] - ECD Automotive Design, Inc. shares decreased by 35% to $0.7521 [9]

Cannabis stocks are once again in the spotlight for investors, with a range of companies in this sector seeing big increases over the past week. www.barchart.com The list of cannabis companies shows extremely diverse year-to-date (YTD) returns, with roughly half the list currently trading down on the year and the other half seeing big gains. More News from Barchart However, among the most notable decliners on this list that's seen a big boost from President Trump's recently announced move to sign an e ...

Betting on early-stage biotech companies is rarely for the faint of heart. Regulatory uncertainty, clinical trial risks, and funding concerns often make these stocks among the market’s most volatile. Yet this year, one of the riskiest biotech companies, AtaiBeckley (ATAI), which makes psychedelic-based mental health therapies, delivered a standout payoff for investors who were willing to take that risk. Atai stock has soared 213% year-to-date (YTD), wildly outperforming the S&P 500 Index’s ($SPX) gain of ...

The dynamics are well understood in an industry where a handful of blockbusters can underwrite years of costly research and where patents may run 20 years on paper, but far less in practice once years of development are taken into account.Pfizer is not alone. Biopharma multinational Bristol Myers Squibb (BMS) chief executive Chris Boerner also warned of a "stacking effect" as multiple drugs lose protection in quick succession."There is clearly a loss of exclusivity wave coming," Bourla said. "This will cost ...